Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the chief executive of Ozempic maker Novo Nordisk warned Wednesday.

Novo Nordisk said on Wednesday it is aware of 10 deaths and 100 hospitalizations resulting from people taking compounded copies of its weight-loss and diabetes drugs, and the CEO said he is alarmed by the risks of the unregulated copycat versions.

Earlier, Novo Nordisk A/S (NYSE:NVO) petitioned the FDA to ban compounding pharmacies from producing cheaper, unapproved versions of its drugs Wegovy and Ozempic. Amid shortages and rising demand for branded drugs,

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least 100 hospitalizations and 10 deaths.